Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Corrigendum: Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aß1-42, and Tau Proteins in Elderly Patients With Mild Cognitive Impairment.

Duron E, Vidal JS, Grousselle D, Gabelle A, Lehmann S, Pasquier F, Bombois S, Buée L, Allinquant B, Schraen-Maschke S, Baret C, Rigaud AS, Hanon O, Epelbaum J.

Front Aging Neurosci. 2019 Feb 19;11:11. doi: 10.3389/fnagi.2019.00011. eCollection 2019.

2.

Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ1-42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment.

Duron E, Vidal JS, Grousselle D, Gabelle A, Lehmann S, Pasquier F, Buée L, Allinquant B, Schraen-Maschke S, Baret C, Rigaud AS, Hanon O, Epelbaum J.

Front Aging Neurosci. 2018 Oct 1;10:297. doi: 10.3389/fnagi.2018.00297. eCollection 2018. Erratum in: Front Aging Neurosci. 2019 Feb 19;11:11.

3.

Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers.

Hanon O, Vidal JS, Lehmann S, Bombois S, Allinquant B, Tréluyer JM, Gelé P, Delmaire C, Blanc F, Mangin JF, Buée L, Touchon J, Hugon J, Vellas B, Galbrun E, Benetos A, Berrut G, Paillaud E, Wallon D, Castelnovo G, Volpe-Gillot L, Paccalin M, Robert PH, Godefroy O, Dantoine T, Camus V, Belmin J, Vandel P, Novella JL, Duron E, Rigaud AS, Schraen-Maschke S, Gabelle A; BALTAZAR study group.

Alzheimers Dement. 2018 Jul;14(7):858-868. doi: 10.1016/j.jalz.2018.01.004. Epub 2018 Feb 17.

4.

Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy.

Laurent C, Dorothée G, Hunot S, Martin E, Monnet Y, Duchamp M, Dong Y, Légeron FP, Leboucher A, Burnouf S, Faivre E, Carvalho K, Caillierez R, Zommer N, Demeyer D, Jouy N, Sazdovitch V, Schraen-Maschke S, Delarasse C, Buée L, Blum D.

Brain. 2017 Jan;140(1):184-200. doi: 10.1093/brain/aww270. Epub 2016 Nov 5.

5.

Differential Mass Spectrometry Profiles of Tau Protein in the Cerebrospinal Fluid of Patients with Alzheimer's Disease, Progressive Supranuclear Palsy, and Dementia with Lewy Bodies.

Barthélemy NR, Gabelle A, Hirtz C, Fenaille F, Sergeant N, Schraen-Maschke S, Vialaret J, Buée L, Junot C, Becher F, Lehmann S.

J Alzheimers Dis. 2016;51(4):1033-43. doi: 10.3233/JAD-150962.

PMID:
26923020
6.

Tau Protein Quantification in Human Cerebrospinal Fluid by Targeted Mass Spectrometry at High Sequence Coverage Provides Insights into Its Primary Structure Heterogeneity.

Barthélemy NR, Fenaille F, Hirtz C, Sergeant N, Schraen-Maschke S, Vialaret J, Buée L, Gabelle A, Junot C, Lehmann S, Becher F.

J Proteome Res. 2016 Feb 5;15(2):667-76. doi: 10.1021/acs.jproteome.5b01001. Epub 2016 Jan 19.

PMID:
26742856
7.

Aβ1-40 and Aβ1-42 Plasmatic Levels In Stroke: Influence of Pre-Existing Cognitive Status and Stroke Characteristics.

Moulin S, Leys D, Schraen-Maschke S, Bombois S, Mendyk AM, Muhr-Tailleux A, Cordonnier C, Buee L, Pasquier F, Bordet R.

Curr Alzheimer Res. 2017;14(6):686-694. doi: 10.2174/1567205012666151027141730. Review.

PMID:
26502812
8.

Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach.

Delaby C, Gabelle A, Blum D, Schraen-Maschke S, Moulinier A, Boulanghien J, Séverac D, Buée L, Rème T, Lehmann S.

Front Neurol. 2015 Aug 24;6:181. doi: 10.3389/fneur.2015.00181. eCollection 2015.

9.

Association of plasma β-amyloid with MRI markers of structural brain aging the 3-City Dijon study.

Kaffashian S, Tzourio C, Soumaré A, Dufouil C, Mazoyer B, Schraen-Maschke S, Buée L, Debette S.

Neurobiol Aging. 2015 Oct;36(10):2663-70. doi: 10.1016/j.neurobiolaging.2015.03.016. Epub 2015 Jul 2.

10.

Plasma β-amyloid and MRI markers of cerebral small vessel disease: Three-City Dijon study.

Kaffashian S, Tzourio C, Soumaré A, Dufouil C, Zhu Y, Crivello F, Maillard P, Schraen-Maschke S, Mazoyer B, Buée L, Debette S.

Neurology. 2014 Nov 25;83(22):2038-45. doi: 10.1212/WNL.0000000000001038. Epub 2014 Oct 29.

11.

Tau exon 2 responsive elements deregulated in myotonic dystrophy type I are proximal to exon 2 and synergistically regulated by MBNL1 and MBNL2.

Carpentier C, Ghanem D, Fernandez-Gomez FJ, Jumeau F, Philippe JV, Freyermuth F, Labudeck A, Eddarkaoui S, Dhaenens CM, Holt I, Behm-Ansmant I, Marmier-Gourrier N, Branlant C, Charlet-Berguerand N, Marie J, Schraen-Maschke S, Buée L, Sergeant N, Caillet-Boudin ML.

Biochim Biophys Acta. 2014 Apr;1842(4):654-64. doi: 10.1016/j.bbadis.2014.01.004. Epub 2014 Jan 14.

12.

MBNL1 gene variants as modifiers of disease severity in myotonic dystrophy type 1.

Huin V, Vasseur F, Schraen-Maschke S, Dhaenens CM, Devos P, Dupont K, Sergeant N, Buée L, Lacour A, Hofmann-Radvanyi H, Sablonnière B.

J Neurol. 2013 Apr;260(4):998-1003. doi: 10.1007/s00415-012-6740-y. Epub 2012 Nov 16.

PMID:
23161457
13.

A new decision tree combining Abeta 1-42 and p-Tau levels in Alzheimer's diagnosis.

Bombois S, Duhamel A, Salleron J, Deramecourt V, Mackowiak MA, Deken V, Sergeant N, Pasquier F, Buée L, Sablonniére B, Schraen-Maschke S.

Curr Alzheimer Res. 2013 May 1;10(4):357-64.

PMID:
23061918
14.

Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach.

Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L.

Curr Alzheimer Res. 2012 May;9(4):397-405.

15.

Association between IgM anti-herpes simplex virus and plasma amyloid-beta levels.

Féart C, Helmer C, Fleury H, Béjot Y, Ritchie K, Amouyel P, Schraen-Maschke S, Buée L, Lambert JC, Letenneur L, Dartigues JF.

PLoS One. 2011;6(12):e29480. doi: 10.1371/journal.pone.0029480. Epub 2011 Dec 28.

16.

Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology.

Belarbi K, Burnouf S, Fernandez-Gomez FJ, Laurent C, Lestavel S, Figeac M, Sultan A, Troquier L, Leboucher A, Caillierez R, Grosjean ME, Demeyer D, Obriot H, Brion I, Barbot B, Galas MC, Staels B, Humez S, Sergeant N, Schraen-Maschke S, Muhr-Tailleux A, Hamdane M, Buée L, Blum D.

Neurobiol Dis. 2011 Aug;43(2):486-94. doi: 10.1016/j.nbd.2011.04.022. Epub 2011 May 4.

PMID:
21569847
17.

Association of plasma Aß peptides with blood pressure in the elderly.

Lambert JC, Dallongeville J, Ellis KA, Schraen-Maschke S, Lui J, Laws S, Dumont J, Richard F, Cottel D, Berr C, Ames D, Masters CL, Rowe CC, Szoeke C, Tzourio C, Dartigues JF, Buée L, Martins R, Amouyel P.

PLoS One. 2011 Apr 15;6(4):e18536. doi: 10.1371/journal.pone.0018536.

18.

Analysis of exonic regions involved in nuclear localization, splicing activity, and dimerization of Muscleblind-like-1 isoforms.

Tran H, Gourrier N, Lemercier-Neuillet C, Dhaenens CM, Vautrin A, Fernandez-Gomez FJ, Arandel L, Carpentier C, Obriot H, Eddarkaoui S, Delattre L, Van Brussels E, Holt I, Morris GE, Sablonnière B, Buée L, Charlet-Berguerand N, Schraen-Maschke S, Furling D, Behm-Ansmant I, Branlant C, Caillet-Boudin ML, Sergeant N.

J Biol Chem. 2011 May 6;286(18):16435-46. doi: 10.1074/jbc.M110.194928. Epub 2011 Mar 18.

19.

Mis-splicing of Tau exon 10 in myotonic dystrophy type 1 is reproduced by overexpression of CELF2 but not by MBNL1 silencing.

Dhaenens CM, Tran H, Frandemiche ML, Carpentier C, Schraen-Maschke S, Sistiaga A, Goicoechea M, Eddarkaoui S, Van Brussels E, Obriot H, Labudeck A, Gevaert MH, Fernandez-Gomez F, Charlet-Berguerand N, Deramecourt V, Maurage CA, Buée L, Lopez de Munain A, Sablonnière B, Caillet-Boudin ML, Sergeant N.

Biochim Biophys Acta. 2011 Jul;1812(7):732-42. doi: 10.1016/j.bbadis.2011.03.010. Epub 2011 Mar 23.

20.

[Molecular actors in Alzheimer's disease: which diagnostic and therapeutic consequences?].

Buée L, Blum D, Bombois S, Buée-Scherrer V, Caillet-Boudin ML, Colin M, Deramecourt V, Dhaenens CM, Galas MC, Hamdane M, Humez S, Maurage CA, Pasquier F, Sablonnière B, Schraen-Maschke S, Sergeant N.

Therapie. 2010 Sep-Oct;65(5):401-7. doi: 10.2515/therapie/2010054. Epub 2010 Dec 13. French.

PMID:
21144474
21.

Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study.

Lambert JC, Schraen-Maschke S, Richard F, Fievet N, Rouaud O, Berr C, Dartigues JF, Tzourio C, Alpérovitch A, Buée L, Amouyel P.

Neurology. 2009 Sep 15;73(11):847-53. doi: 10.1212/WNL.0b013e3181b78448.

PMID:
19752451
22.

[Biological markers in Alzheimer disease: what are the chances for less slow diagnosis?].

Schraen-Maschke S, Dhaenens CM, Bombois S, Deramecourt V, Van Brussel E, Obriot H, Marzys C, Sergeant N, Maurage CA, Pasquier F, Sablonnière B, Buée L.

Rev Neurol (Paris). 2009 Apr;165 Spec No 2:F97-103. Review. French. No abstract available.

PMID:
19593884
23.

Altered splicing of Tau in DM1 is different from the foetal splicing process.

Ghanem D, Tran H, Dhaenens CM, Schraen-Maschke S, Sablonnière B, Buée L, Sergeant N, Caillet-Boudin ML.

FEBS Lett. 2009 Feb 18;583(4):675-9. doi: 10.1016/j.febslet.2008.12.065. Epub 2009 Jan 21.

24.

Tau as a biomarker of neurodegenerative diseases.

Schraen-Maschke S, Sergeant N, Dhaenens CM, Bombois S, Deramecourt V, Caillet-Boudin ML, Pasquier F, Maurage CA, Sablonnière B, Vanmechelen E, Buée L.

Biomark Med. 2008 Aug;2(4):363-84. doi: 10.2217/17520363.2.4.363.

25.

Biochemistry of Tau in Alzheimer's disease and related neurological disorders.

Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin ML, Grognet P, Bombois S, Blum D, Delacourte A, Pasquier F, Vanmechelen E, Schraen-Maschke S, Buée L.

Expert Rev Proteomics. 2008 Apr;5(2):207-24. doi: 10.1586/14789450.5.2.207. Review.

PMID:
18466052
26.

Overexpression of MBNL1 fetal isoforms and modified splicing of Tau in the DM1 brain: two individual consequences of CUG trinucleotide repeats.

Dhaenens CM, Schraen-Maschke S, Tran H, Vingtdeux V, Ghanem D, Leroy O, Delplanque J, Vanbrussel E, Delacourte A, Vermersch P, Maurage CA, Gruffat H, Sergeant A, Mahadevan MS, Ishiura S, Buée L, Cooper TA, Caillet-Boudin ML, Charlet-Berguerand N, Sablonnière B, Sergeant N.

Exp Neurol. 2008 Apr;210(2):467-78. doi: 10.1016/j.expneurol.2007.11.020. Epub 2007 Dec 4.

PMID:
18177861
27.

ETR-3 represses Tau exons 2/3 inclusion, a splicing event abnormally enhanced in myotonic dystrophy type I.

Leroy O, Dhaenens CM, Schraen-Maschke S, Belarbi K, Delacourte A, Andreadis A, Sablonnière B, Buée L, Sergeant N, Caillet-Boudin ML.

J Neurosci Res. 2006 Sep;84(4):852-9.

PMID:
16862542
28.

Association study of three polymorphisms of kinesin light-chain 1 gene with Alzheimer's disease.

Dhaenens CM, Van Brussel E, Schraen-Maschke S, Pasquier F, Delacourte A, Sablonnière B.

Neurosci Lett. 2004 Sep 30;368(3):290-2.

PMID:
15364413
29.

Microtubule-associated protein tau gene: a risk factor in human neurodegenerative diseases.

Schraen-Maschke S, Dhaenens CM, Delacourte A, Sablonnière B.

Neurobiol Dis. 2004 Apr;15(3):449-60. Review.

PMID:
15056452
30.

Diffuse form of argyrophilic grain disease: a new variant of four-repeat tauopathy different from limbic argyrophilic grain disease.

Maurage CA, Sergeant N, Schraen-Maschke S, Lebert F, Ruchoux MM, Sablonnière B, Pasquier F, Delacourte A.

Acta Neuropathol. 2003 Dec;106(6):575-83. Epub 2003 Sep 27.

PMID:
14517683
31.

Role of oligomannosidic N-glycans in the proliferation, adhesion and signalling of C6 glioblastoma cells.

Schraen-Maschke S, Zanetta JP.

Biochimie. 2003 Jan-Feb;85(1-2):219-29.

PMID:
12765791
32.

The novel retinoid AHPN/CD437 induces a rapid but incomplete apoptotic response in human myeloma cells.

Joseph B, Marchetti P, Lefebvre O, Schraen-Maschke S, Méreau-Richard C, Formstecher P.

Biochim Biophys Acta. 2003 Feb 17;1593(2-3):277-82.

33.

A new locus for spinocerebellar ataxia (SCA21) maps to chromosome 7p21.3-p15.1.

Vuillaume I, Devos D, Schraen-Maschke S, Dina C, Lemainque A, Vasseur F, Bocquillon G, Devos P, Kocinski C, Marzys C, Destée A, Sablonnière B.

Ann Neurol. 2002 Nov;52(5):666-70.

PMID:
12402269
34.

Real time RT-PCR shows correlation between retinoid-induced apoptosis and NGF-R mRNA levels.

Vuillaume I, Schraen-Maschke S, Formstecher P, Sablonnière B.

Biochem Biophys Res Commun. 2001 Dec 7;289(3):647-52.

PMID:
11726196
35.

Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1.

Sergeant N, Sablonnière B, Schraen-Maschke S, Ghestem A, Maurage CA, Wattez A, Vermersch P, Delacourte A.

Hum Mol Genet. 2001 Sep 15;10(19):2143-55.

PMID:
11590131
36.

Clinical features and genetic analysis of a new form of spinocerebellar ataxia.

Devos D, Schraen-Maschke S, Vuillaume I, Dujardin K, Nazé P, Willoteaux C, Destée A, Sablonnière B.

Neurology. 2001 Jan 23;56(2):234-8.

PMID:
11160961
37.

The first identified French family with dentatorubral-pallidoluysian atrophy.

Destée A, Delalande I, Vuillaume I, Schraen-Maschke S, Defebvre L, Sablonnière B.

Mov Disord. 2000 Sep;15(5):996-9.

PMID:
11009212
38.

[Triplet expansion diseases].

Sablonnière B, Vuillaume I, Schraen-Maschke S.

Ann Biol Clin (Paris). 2000 May-Jun;58(3):356-60. Review. French. No abstract available.

39.

Absence of unidentified CAG repeat expansion in patients with Huntington's disease-like phenotype.

Vuillaume I, Meynieu P, Schraen-Maschke S, Destée A, Sablonnière B.

J Neurol Neurosurg Psychiatry. 2000 May;68(5):672-5.

40.

The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus.

Marchetti P, Zamzami N, Joseph B, Schraen-Maschke S, Méreau-Richard C, Costantini P, Métivier D, Susin SA, Kroemer G, Formstecher P.

Cancer Res. 1999 Dec 15;59(24):6257-66.

41.

Analysis of ERDA1, CTG18.1, and uncloned CAG/CTG repeat sequences in familial Parkinson's disease with anticipation.

Schraen-Maschke S, Brique S, Chartier-Harlin MC, Brique E, Destée A, Sablonnière B.

Am J Med Genet. 1999 Dec 15;88(6):738-41.

PMID:
10581499

Supplemental Content

Loading ...
Support Center